Detalhe da pesquisa
1.
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
Nat Genet
; 36(5): 453-61, 2004 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15098032
2.
Discovery of Potent, Highly Selective, and In Vivo Efficacious, Allosteric MALT1 Inhibitors by Iterative Scaffold Morphing.
J Med Chem
; 63(23): 14576-14593, 2020 12 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33252239
3.
Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis.
Cardiovasc Res
; 79(1): 118-26, 2008 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18326555
4.
Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.
Eur J Pharmacol
; 599(1-3): 44-53, 2008 Dec 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-18938156
5.
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug.
Nat Rev Drug Discov
; 1(7): 493-502, 2002 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-12120256
6.
The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
Clin Cancer Res
; 11(4): 1563-71, 2005 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15746061
7.
Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.
Cancer Res
; 62(19): 5476-84, 2002 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12359756
8.
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
Cancer Res
; 64(7): 2333-7, 2004 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15059881
9.
Oral imatinib mesylate (STI571/gleevec) improves the efficacy of local intravascular vascular endothelial growth factor-C gene transfer in reducing neointimal growth in hypercholesterolemic rabbits.
Circulation
; 109(9): 1140-6, 2004 Mar 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-14769706
10.
Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Mol Cancer Res
; 1(2): 89-95, 2002 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-12496355
11.
Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
Pharmacol Ther
; 93(2-3): 79-98, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-12191602
12.
STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake.
Clin Cancer Res
; 9(10 Pt 1): 3779-87, 2003 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-14506171
13.
The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.
Mol Cancer Ther
; 3(5): 527-35, 2004 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15141010
14.
Pharmacology of imatinib (STI571).
Eur J Cancer
; 38 Suppl 5: S28-36, 2002 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-12528770
15.
Platelet-derived growth factor receptor inhibition reduces allograft arteriosclerosis of heart and aorta in cholesterol-fed rabbits.
Transplantation
; 75(3): 334-9, 2003 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12589154
16.
[Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia]. / Bcr-Abl-Hemmung als molekularer Therapieansatz bei der chronischen myeloischen Leukämie.
Med Klin (Munich)
; 97 Suppl 1: 2-6, 2002 Jan 15.
Artigo
em Alemão
| MEDLINE | ID: mdl-11831067
17.
The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib®).
Int J Oncol
; 45(6): 2267-77, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25340839
18.
The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
Blood
; 105(7): 2640-53, 2005 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15618470
19.
Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.
J Biol Chem
; 277(35): 32214-9, 2002 Aug 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-12077114
20.
Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases.
Blood
; 101(2): 664-72, 2003 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12393636